Nurix Therapeutics Inc (NRIX)
22.05
-0.32
(-1.43%)
USD |
NASDAQ |
Nov 22, 16:00
21.50
-0.55
(-2.49%)
After-Hours: 20:00
Nurix Therapeutics Enterprise Value: 1.114B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 1.114B |
| November 21, 2024 | 1.137B |
| November 20, 2024 | 1.156B |
| November 19, 2024 | 1.166B |
| November 18, 2024 | 1.095B |
| November 15, 2024 | 1.176B |
| November 14, 2024 | 1.455B |
| November 13, 2024 | 1.475B |
| November 12, 2024 | 1.467B |
| November 11, 2024 | 1.545B |
| November 08, 2024 | 1.489B |
| November 07, 2024 | 1.482B |
| November 06, 2024 | 1.465B |
| November 05, 2024 | 1.353B |
| November 04, 2024 | 1.326B |
| November 01, 2024 | 1.285B |
| October 31, 2024 | 1.293B |
| October 30, 2024 | 1.257B |
| October 29, 2024 | 1.337B |
| October 28, 2024 | 1.426B |
| October 25, 2024 | 1.413B |
| October 24, 2024 | 1.338B |
| October 23, 2024 | 1.307B |
| October 22, 2024 | 1.360B |
| October 21, 2024 | 1.357B |
| Date | Value |
|---|---|
| October 18, 2024 | 1.326B |
| October 17, 2024 | 1.303B |
| October 16, 2024 | 1.380B |
| October 15, 2024 | 1.314B |
| October 14, 2024 | 1.334B |
| October 11, 2024 | 1.226B |
| October 10, 2024 | 1.100B |
| October 09, 2024 | 1.027B |
| October 08, 2024 | 1.028B |
| October 07, 2024 | 996.93M |
| October 04, 2024 | 1.041B |
| October 03, 2024 | 1.006B |
| October 02, 2024 | 1.026B |
| October 01, 2024 | 1.034B |
| September 30, 2024 | 1.059B |
| September 27, 2024 | 1.098B |
| September 26, 2024 | 1.109B |
| September 25, 2024 | 1.130B |
| September 24, 2024 | 1.181B |
| September 23, 2024 | 1.169B |
| September 20, 2024 | 1.271B |
| September 19, 2024 | 1.233B |
| September 18, 2024 | 1.212B |
| September 17, 2024 | 1.218B |
| September 16, 2024 | 1.259B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-52.71M
Minimum
Oct 25 2023
1.734B
Maximum
Mar 17 2021
606.85M
Average
527.63M
Median
Jul 28 2020
Enterprise Value Benchmarks
| Enzo Biochem Inc | -1.429M |
| Neogen Corp | 4.015B |
| Pfizer Inc | 202.30B |
| Zymeworks Inc | 687.06M |
| Accolade Inc | 272.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.96M |
| Revenue (Quarterly) | 12.59M |
| Total Expenses (Quarterly) | 67.20M |
| EPS Diluted (Quarterly) | -0.67 |
| Profit Margin (Quarterly) | -388.9% |
| Earnings Yield | -13.20% |
| Normalized Earnings Yield | -13.20 |